
CITATION REPORT List of articles citing



DOI: 10.1056/nejme2020388 New England Journal of Medicine, 2020, 383, 585-586.

Source: https://exaly.com/paper-pdf/76672057/citation-report.pdf

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
79	"Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors - A survey". <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020 , 14, 1413-141	18 ^{8.9}	2
78	Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106101	14.3	52
77	Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. <i>EClinicalMedicine</i> , 2020 , 29, 100645	11.3	34
76	The Flood of COVID-19 Publications: a Word of Caution. <i>SN Comprehensive Clinical Medicine</i> , 2020 , 2, 1-3	2.7	2
75	Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline. <i>RMD Open</i> , 2020 , 6,	5.9	О
74	COVID-19 and Systemic Lupus Erythematosus: Focus on Immune Response and Therapeutics. <i>Frontiers in Immunology</i> , 2020 , 11, 589474	8.4	25
73	Stem cell therapy for COVID-19: Possibilities and challenges. <i>Cell Biology International</i> , 2020 , 44, 2182-2	2149.5	29
72	Chloroquine and hydroxychloroquine for COVID-19: time to close the chapter. <i>Postgraduate Medical Journal</i> , 2021 , 97, 676-677	2	7
71	COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. <i>PLoS Medicine</i> , 2020 , 17, e1003252	11.6	55
70	Artificial intelligence, drug repurposing and peer review. <i>Nature Biotechnology</i> , 2020 , 38, 1127-1131	44.5	35
69	Hydroxychloroquine as Prophylaxis for COVID-19: A Review. Frontiers in Pharmacology, 2020 , 11, 60518	5 5.6	5
68	COVID-19 research: an opinion piece. HIV Medicine, 2020, 21, 536-540	2.7	3
67	Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: Rhydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?Rby Xie. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e7	2.4	4
66	Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 19, 5-16	5.5	15
65	Myocarditis and coronary aneurysms in a child with acute respiratory syndrome coronavirus 2. <i>ESC Heart Failure</i> , 2021 , 8, 761-765	3.7	5
64	Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , 2021 , 181, 195-202	11.5	102
63	A pandemic of cognitive bias. <i>Intensive Care Medicine</i> , 2021 , 47, 636-637	14.5	3

(2021-2021)

62	COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. <i>Rheumatology International</i> , 2021 , 41, 257-273	3.6	О
61	Different Versions of Atom-Bond Connectivity Indices of Some Molecular Structures: Applied for the Treatment and Prevention of COVID-19. <i>Polycyclic Aromatic Compounds</i> , 1-15	1.3	2
60	Skin Damage Induced by Enhanced Protective Measures in Frontline Doctors During Covid-19 Pandemic: A Web-Based Descriptive Study. <i>Indian Journal of Dermatology</i> , 2021 , 66, 145-150	0.9	
59	The Rise and Fall of Hydroxychloroquine for the Treatment and Prevention of COVID-19. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021 , 104, 35-38	3.2	13
58	COVID-19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations. <i>Journal of Medical Virology</i> , 2021 , 93, 2694-2704	19.7	9
57	An indirect method to monitor the fraction of people ever infected with COVID-19: An application to the United States. <i>PLoS ONE</i> , 2021 , 16, e0245845	3.7	7
56	Therapeutic Strategies in the Management of COVID-19. Frontiers in Molecular Biosciences, 2020, 7, 636	738	8
55	Choppy waters: The importance of accounting for shifting drug utilization during the COVID-19 pandemic in future observational drug-related studies. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021 , 128, 649-651	3.1	1
54	Chyawanprash for the prevention of COVID-19 infection among healthcare workers: A Randomized Controlled Trial.		4
53	Modeling the Effect of Population-Wide Vaccination on the Evolution of COVID-19 Epidemic in Canada.		4
52	MicroRNAs and Long Non-Coding RNAs as Potential Candidates to Target Specific Motifs of SARS-CoV-2. <i>Non-coding RNA</i> , 2021 , 7,	7.1	17
51	Care for Patients With Neuromuscular Disorders in the COVID-19 Pandemic Era. <i>Frontiers in Neurology</i> , 2021 , 12, 607790	4.1	5
50	CYP2D6 and CYP3A4 variants influence the risk and outcome of COVID-19 infection among rheumatoid arthritis patients maintained on hydroxychloroquine. <i>Drug Metabolism and Personalized Therapy</i> , 2021 ,	2	0
49	An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?. Frontiers in Pharmacology, 2021 , 12, 632677	5.6	28
48	Nanocarrier vaccines for SARS-CoV-2. Advanced Drug Delivery Reviews, 2021, 171, 215-239	18.5	37
48	Nanocarrier vaccines for SARS-CoV-2. <i>Advanced Drug Delivery Reviews</i> , 2021 , 171, 215-239 Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review. <i>Therapeutics and Clinical Risk Management</i> , 2021 , 17, 371-387	18.5	37
	Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction,		

Hydroxychloroquine as prophylaxis when treating patients with coronavirus disease 2019 \square 44 Perception of frontline health care workers in South India. Indian Journal of Medical Sciences, 73, 141-146 Unraveling the unbinding pathways of SARS-CoV-2 Papain-like proteinase known inhibitors by 43 *3*·7 Supervised Molecular Dynamics simulation. *PLoS ONE*, **2021**, 16, e0251910 Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying 42 2 3.9 anti-rheumatic drugs. Clinical Rheumatology, 2021, 40, 4309-4315 Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?. International Journal of 41 6.3 Molecular Sciences, 2021, 22, Pathogenesis-based preexposure prophylaxis associated with a low risk of SARS-CoV-2 infection in

40	healthcare workers at a designated COVID-19 hospital: a pilot study. <i>BMC Infectious Diseases</i> , 2021 , 21, 536	4	2
39	Drug targets, mechanisms of drug action, and therapeutics against SARS-CoV-2. <i>Chemical Physics Impact</i> , 2021 , 2, 100011	1.6	10
38	Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19. <i>Npj Regenerative Medicine</i> , 2021 , 6, 37	15.8	10
37	An in vitro antiviral activity of iodine complexes against SARS-CoV-2. <i>Archives of Microbiology</i> , 2021 , 203, 4743-4749	3	1
36	Cold atmospheric plasma: A non-negligible strategy for viral RNA inactivation to prevent SARS-CoV-2 environmental transmission. <i>AIP Advances</i> , 2021 , 11, 085019	1.5	5
35	Theory and reality of antivirals against SARS-CoV-2. World Journal of Clinical Cases, 2021, 9, 6663-6673	1.6	O
34	State of Sweat: Emerging Wearable Systems for Real-Time, Noninvasive Sweat Sensing and Analytics. <i>ACS Sensors</i> , 2021 , 6, 2787-2801	9.2	23
33	. Revue Du Rhumatisme (Edition Francaise), 2021 ,	0.1	O
32	Clinical trials with antiviral drugs against COVID-19: some progress and many shattered hopes. <i>Environmental Microbiology</i> , 2021 , 23, 6364-6376	5.2	4
31	Impact of hydroxychloroquine used as DMARD on SARS-CoV-2 tests and infection evolution in a population of 871 patients with inflammatory rheumatic and musculoskeletal diseases. <i>Joint Bone Spine</i> , 2021 , 88, 105226	2.9	3
30	Pharmacotherapeutics of SARS-CoV-2 Infections. <i>Journal of NeuroImmune Pharmacology</i> , 2021 , 16, 12-3	8 7 6.9	3
29	Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. <i>Drug Resistance Updates</i> , 2020 , 53, 100721	23.2	44
28	An in vitro assessment of anti-SARS-CoV-2 activity of oral preparations of iodine complexes (RENESSANS).		1
27	Effective post-exposure prophylaxis of Covid-19 is associated with use of hydroxychloroquine: Prospective re-analysis of a public dataset incorporating novel data.		2

26	A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2. 2020 ,		8
25	Preparedness and guidelines for neurosurgery in the COVID-19 era: Indian perspective from a tertiary care referral hospital. <i>Neurosurgical Focus</i> , 2020 , 49, E3	4.2	5
24	Hydroxychloroquine, Arbidol and COVID-19: The Jury is Still Out!. <i>Current Respiratory Medicine Reviews</i> , 2021 , 17, 2-2	0.3	
23	Preventing disease after exposure to COVID-19 using hydroxychloroquine: A summary of a protocol for exploratory re-analysis of age and time-nuanced effects.		2
22	Progress in the risk assessment of hydroxychloroquine in frail elderly people. <i>Aging Medicine</i> (Milton (N S W)), 2021 , 4, 53-57	3.5	
21	Potentials of Interferons and Hydroxychloroquine for the Prophylaxis and Early Treatment of COVID-19. <i>Journal of Cellular Immunology</i> , 2020 , 2, 333-340	1.9	O
20	Hydroxychloroquine: the story of one drug during the COVID-19 pandemic. <i>Profilakticheskaya Meditsina</i> , 2020 , 123, 74	0.5	
19	Prophylactic use of hydroxychloroquine among healthcare workers in a case-control study. <i>Indian Journal of Medical Research</i> , 2020 , 152, 127-128	2.9	О
18	AuthorsRresponse. <i>Indian Journal of Medical Research</i> , 2020 , 152, 120	2.9	
17	Pathogenesis-based pre-exposure prophylaxis associated with low risk of SARS-CoV-2 infection in healthcare workers at a designated Covid-19 hospital.		1
16	Knowledge, Attitude and Practice with Regard to Preventive Measures of Covid-19 across Community in the above 18-Years Age Group in Nandyal District, Andhra Pradesh, India. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2020 , 7, 2872-2878	O	
15	A Multifunctional Neutralizing Antibody-Conjugated Nanoparticle Inhibits and Inactivates SARS-CoV-2. <i>Advanced Science</i> , 2021 , e2103240	13.6	3
14	Natural Bioactive Molecules: An Alternative Approach to the Treatment and Control of COVID-19. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	15
13	Hydroxychloroquine/Chloroquine for the Treatment of Hospitalized Patients with COVID-19: An Individual Participant Data Meta-Analysis 2022 ,		1
12	"The new normal"? Lessons from the treatment of emerging infectious diseases with old drugs <i>Revista Portuguesa De Cardiologia</i> , 2022 , 41, 165-165	1	
11	Hydroxychloroquine/Chloroquine in COVID-19 With Focus on Hospitalized Patients 🖪 Systematic Review.		O
10	Contradictory or complementary? StakeholdersRperceptions of a circular economy for single-use plastics <i>Waste Management</i> , 2022 , 142, 1-8	8.6	О
9	Efficacy of polyherbal formulations for prevention of COVID -19 infection in high-risk subjects: A randomized open-label controlled clinical trial. <i>Phytotherapy Research</i> ,	6.7	1

8	Tissue repair strategies: What we have learned from COVID-19 in the application of MSCs therapy. <i>Pharmacological Research</i> , 2022 , 182, 106334	10.2 1	
7	Sports Participation and Anti-Epidemic: Empirical Evidence on the Influence of Regular Physical Activity on the COVID-19 Pandemic in Mainland China. 2022 , 19, 10689	O	
6	Putative Therapeutic Impact of Inflammasome Inhibitors against COVID-19-Induced ARDS. 2022 , 29,	0	
5	Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis. 2022 , 17, e0273526	0	
4	CYP2D6 and CYP3A4 variants influence the risk and outcome of COVID-19 infection among rheumatoid arthritis patients maintained on hydroxychloroquine. 2021 , 36, 99-111	O	
3	Unit information prior for incorporating real-world evidence into randomized controlled trials. 2023 , 32, 229-241	0	
2	ADR profile among healthcare workers on Hydroxychloroquine prophylaxis in a tertiary care teaching hospital in India. 2022 , 5202-5205	0	
1	Clinical considerations with use of psychotropic medications in COVID-19 patients. 2022 , 18, 59	0	